Paradigm Biopharmaceuticals Limited Stock Price Patterns
| PBIGF Stock | USD 0.22 0.00 0.00% |
Momentum 39
Sell Extended
Oversold | Overbought |
Using Paradigm Biopharmaceutica hype-based prediction, you can estimate the value of Paradigm Biopharmaceuticals Limited from the perspective of Paradigm Biopharmaceutica response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Paradigm Biopharmaceutica to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Paradigm because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Paradigm Biopharmaceutica after-hype prediction price | USD 0.22 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Paradigm |
Paradigm Biopharmaceutica After-Hype Price Density Analysis
As far as predicting the price of Paradigm Biopharmaceutica at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Paradigm Biopharmaceutica or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Paradigm Biopharmaceutica, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Paradigm Biopharmaceutica Estimiated After-Hype Price Volatility
In the context of predicting Paradigm Biopharmaceutica's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Paradigm Biopharmaceutica's historical news coverage. Paradigm Biopharmaceutica's after-hype downside and upside margins for the prediction period are 0.01 and 6.05, respectively. We have considered Paradigm Biopharmaceutica's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Paradigm Biopharmaceutica is out of control at this time. Analysis and calculation of next after-hype price of Paradigm Biopharmaceutica is based on 3 months time horizon.
Paradigm Biopharmaceutica Pink Sheet Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Paradigm Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Paradigm Biopharmaceutica backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Paradigm Biopharmaceutica, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.22 | 5.83 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.22 | 0.22 | 0.00 |
|
Paradigm Biopharmaceutica Hype Timeline
Paradigm Biopharmaceutica is at this time traded for 0.22. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Paradigm is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -0.22%. %. The volatility of related hype on Paradigm Biopharmaceutica is about 0.0%, with the expected price after the next announcement by competition of 0.22. About 16.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.14. Paradigm Biopharmaceutica had not issued any dividends in recent years. Assuming the 90 days horizon the next forecasted press release will be within a week. Check out Paradigm Biopharmaceutica Basic Forecasting Models to cross-verify your projections.Paradigm Biopharmaceutica Related Hype Analysis
Having access to credible news sources related to Paradigm Biopharmaceutica's direct competition is more important than ever and may enhance your ability to predict Paradigm Biopharmaceutica's future price movements. Getting to know how Paradigm Biopharmaceutica's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Paradigm Biopharmaceutica may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| POLBF | Poolbeg Pharma PLC | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| KNTPF | Kintor Pharmaceutical Limited | 0.00 | 0 per month | 0.00 | 0.07 | 0.00 | 0.00 | 32.99 | |
| IUGNF | Imugene Limited | 0.00 | 0 per month | 6.80 | 0.02 | 25.00 | (13.64) | 47.15 | |
| VSBC | VitaSpring Biomedical Co | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MSCLF | Satellos Bioscience | 0.00 | 0 per month | 3.40 | 0.17 | 10.37 | (5.77) | 22.60 | |
| SHIEF | Shield Therapeutics plc | 0.00 | 0 per month | 0.00 | 0.10 | 7.14 | 0.00 | 61.79 | |
| SPHRY | Starpharma Holdings | 0.00 | 0 per month | 2.93 | 0.03 | 7.00 | (6.38) | 33.24 | |
| PFGTF | Pacific Edge Limited | 0.00 | 0 per month | 0.00 | (0.03) | 0.00 | 0.00 | 99.18 | |
| AURX | Nuo Therapeutics | 0.00 | 0 per month | 0.00 | (0.11) | 7.50 | (7.45) | 23.25 | |
| ORXOF | Orexo AB | 0.00 | 0 per month | 0.00 | (0.01) | 0.00 | 0.00 | 5.90 |
Paradigm Biopharmaceutica Additional Predictive Modules
Most predictive techniques to examine Paradigm price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Paradigm using various technical indicators. When you analyze Paradigm charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Paradigm Biopharmaceutica Predictive Indicators
The successful prediction of Paradigm Biopharmaceutica stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Paradigm Biopharmaceuticals Limited, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Paradigm Biopharmaceutica based on analysis of Paradigm Biopharmaceutica hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Paradigm Biopharmaceutica's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Paradigm Biopharmaceutica's related companies.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Complementary Tools for Paradigm Pink Sheet analysis
When running Paradigm Biopharmaceutica's price analysis, check to measure Paradigm Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Paradigm Biopharmaceutica is operating at the current time. Most of Paradigm Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Paradigm Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Paradigm Biopharmaceutica's price. Additionally, you may evaluate how the addition of Paradigm Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |